Zobrazeno 1 - 10
of 239
pro vyhledávání: '"Miguel F Sanmamed"'
Autor:
Pedro Berraondo, Ignacio Melero, Miguel F Sanmamed, Carlos E De Andrea, María Campos, Iñaki Eguren-Santamaria, Eva Fernández de Piérola, Gracián Camps, Paula Martín-Muñoz, Doina Cuculescu, Inmaculada Aguilera-Buenosvinos, Inmaculada Rodríguez López, Rafael Salido-Vallejo, Raluca Alexandru, Laura Álvarez-Gigli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 9 (2024)
Background Immunodeficient mice engrafted with peripheral blood mononuclear cells (PBMCs) are models to study new cancer immunotherapy agents. However, this approach is associated with xenograft-versus-host disease (xGVHD), which starts early after P
Externí odkaz:
https://doaj.org/article/bf82f9c0cbf94be6a1a8d4e73fac748e
Autor:
Roy S Herbst, Lieping Chen, David L Rimm, Miguel F Sanmamed, Kurt A Schalper, Alice Li, Konstantinos Syrigos, Jovian Yu, Adam Aguirre-Ducler, Brian S Henick, Franz Villarroel-Espindola, Ila Datar, Shruti Desai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Despite the prominent role of innate immunity in the antitumor response, little is known about the myeloid composition of human non-small cell lung cancer (NSCLC) with respect to histology and molecular subtype. We used multiplexed quantit
Externí odkaz:
https://doaj.org/article/8666dac9e47e49ac8886f836aa022847
Autor:
Arantza Azpilikueta, Ignacio Melero, Sonia Guedan, Alvaro Teijeira, Lieping Chen, Maria C Ochoa, Maite Alvarez, Jose Luis Perez Gracia, Maria E Rodriguez-Ruiz, Miguel F Sanmamed, Assunta Cirella, Javier Glez-Vaz, Irene Olivera, Iñaki Eguren-Santamaria, Carlos Luri-Rey, Xinxin Nie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background On the basis of efficacy in mouse tumor models, multiple CD137 (4-1BB) agonist agents are being preclinically and clinically developed. The costimulatory molecule CD137 is inducibly expressed as a transmembrane or as a soluble protein (sCD
Externí odkaz:
https://doaj.org/article/73397a239a8744e29c59d4accc19c284
Autor:
Pedro Berraondo, Ignacio Melero, Alvaro Teijeira, Carmen Molina, Marisol Quintero, Fernando Aranda, Maite Alvarez, Maria E Rodriguez-Ruiz, Xinyi Fan, Miguel F Sanmamed, Javier Glez-Vaz, Maria Villalba, Carlos E De Andrea, Myriam Fernandez-Sendin, Jose Gonzalez-Gomariz, Maria Carmen Ochoa, Wen H Shen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/9fb53e88bcd34935a6e8063f150d12bc
Autor:
Hendrik-Tobias Arkenau, Jean-Yves Douillard, Nicolas Penel, Teresa Amaral, Ahmad Awada, Emiliano Calvo, Viktor Gruenwald, Jose Luis Perez-Gracia, Ruth Vera, Martijn P Lolkema, Gyorgy Bodoky, Massimo Di Nicola, Miguel F Sanmamed
Publikováno v:
ESMO Open, Vol 5, Iss 3 (2020)
During the last years, there has been a dramatic increase in the administrative and bureaucratic burden associated with clinical research, which has clearly had an impact on its overall efficiency and on the activity of clinical investigators and res
Externí odkaz:
https://doaj.org/article/c8d312d3e1a44b40a040f3c31e8a35a2
Autor:
Paolo A. Ascierto, Mario Mandalà, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni
Publikováno v:
Journal of Clinical Oncology. 41:212-221
PURPOSE Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c30293afb06231294ca927cf8d574589
https://doi.org/10.1200/jco.21.02961
https://doi.org/10.1200/jco.21.02961
Autor:
Assunta Cirella, Elixabet Bolaños, Claudia Augusta Di Trani, Carlos E. de Andrea, Sandra Sánchez-Gregorio, Iñaki Etxeberria, Jose Gonzalez-Gomariz, Irene Olivera, Davide Brocco, Javier Glez-Vaz, Carlos Luri-Rey, Arantza Azpilikueta, Inmaculada Rodríguez, Myriam Fernandez-Sendín, Josune Egea, Iñaki Eguren, Miguel F. Sanmamed, Belen Palencia, Alvaro Teijeira, Pedro Berraondo, Ignacio Melero
Publikováno v:
Cancer Immunology Research. 11:184-198
IL12-based local gene therapy of cancer constitutes an active area of clinical research using plasmids, mRNAs, and viral vectors. To improve antitumor effects, we have experimentally tested the combination of mRNA constructs encoding IL12 and IL18. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9a8397403353a6bbc17c21071b64cb8
https://doi.org/10.1158/2326-6066.cir-22-0373
https://doi.org/10.1158/2326-6066.cir-22-0373
Autor:
Maria C. Ochoa, Elisabeth Perez-Ruiz, Luna Minute, Carmen Oñate, Guiomar Perez, Inmaculada Rodriguez, Aintzane Zabaleta, Diego Alignani, Myriam Fernandez-Sendin, Ascension Lopez, Aura Muntasell, Miguel F. Sanmamed, Bruno Paiva, Miguel Lopez-Botet, Pedro Berraondo, Ignacio Melero
Publikováno v:
OncoImmunology, Vol 8, Iss 7 (2019)
Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells. NK cells acquire surface CD13
Externí odkaz:
https://doaj.org/article/469445f7b4c148028345cf1278b80df7
Autor:
Ignacio Melero, Tamara Tanos, Mariana Bustamante, Miguel F. Sanmamed, Emiliano Calvo, Irene Moreno, Victor Moreno, Tatiana Hernandez, Maria Martinez Garcia, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Rohrberg, Ernesto Guarin, Eveline Nüesch, Iakov I. Davydov, Chiahuey Ooi, José Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Cañamero, Oliver Krieter
Publikováno v:
Science Translational Medicine. 15
This first-in-human study evaluated RO7122290, a bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein α (FAP) binding site that costimulates T cells for improved tumor cell killing in FAP-expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c21d1128067bd586b01f93f4a042a37a
https://doi.org/10.1126/scitranslmed.abp9229
https://doi.org/10.1126/scitranslmed.abp9229
Autor:
Ignacio Melero, Álvaro Teijeira, Frances R. Balkwill, Pedro Berraondo, Carlos E. de Andrea, David Propper, Beatrice Malacrida, María C. Ochoa, Maite Alvarez, Arantza Azpilikueta, Javier Glez-Vaz, Miguel F. Sanmamed, Iñaki Eguren-Santamaria, Itziar Migueliz, Saray Garasa, Josune Egea, Assunta Cirella, Iñaki Etxeberria, Inmaculada Rodriguez, Elixabet Bolaños, Rebeca Sanz-Pamplona, Irene Olivera
Supplementary Figure from A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f32d8b6c5cd605ff447850ccc7e59f0
https://doi.org/10.1158/2159-8290.22541500.v1
https://doi.org/10.1158/2159-8290.22541500.v1
